Dergiler / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 2

Anti-HDV seroprevalance among patients with previous HBV infection

Sayfa
132–138
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Longtermfollow-up studies, including after the resolution of both infections, are needed to explore HBV–HDV interactions and thebehavioral patterns of these viruses.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: This prospective study aimed to determine the prevalence of anti-HDV seropositivity among subjects who hadprevious hepatitis B virus (HBV) infection.METHODS: Subjects who were admitted to the gastroenterology inpatient clinic of our hospital between August 2016 andJuly 2017 were screened for previous HBV infection.
📊
Temel Bulgular & Veri:Subjects who were anti-HDV positive were recalled for a control visit, and HBV-DNA and HDV-RNA wereassayed in the blood samples of the responders.RESULTS: Among 554 subjects who had previous HBV infection, 53 (9.6%) were anti-HDV positive.
💡
Sonuç & Katkı:Longtermfollow-up studies, including after the resolution of both infections, are needed to explore HBV–HDV interactions and thebehavioral patterns of these viruses.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: This prospective study aimed to determine the prevalence of anti-HDV seropositivity among subjects who hadprevious hepatitis B virus (HBV) infection.METHODS: Subjects who were admitted to the gastroenterology inpatient clinic of our hospital between August 2016 andJuly 2017 were screened for previous HBV infection. The subjects who had HBV serology compatible with resolved HBVinfection were recruited in the study, and the seroprevalance of anti-HDV was studied. Participants answered a short questionnaireregarding their family history of chronic hepatitis B (CHB) and chronic hepatitis D (CHD) infection and risk factorsfor transmission. Subjects who were anti-HDV positive were recalled for a control visit, and HBV-DNA and HDV-RNA wereassayed in the blood samples of the responders.RESULTS: Among 554 subjects who had previous HBV infection, 53 (9.6%) were anti-HDV positive. The mean age was63.1±15.4 years in the anti-HDV-positive group and 65.9±15.6 years in the anti-HDV-negative group (p=0.19). The mostcommon risk factor for both groups was dental procedures (89% vs 80%, p=0.33). Anti-Hbc IgG, anti-Hbs, and anti-HBeAgseropositivity did not differ between the anti-HDV-positive and -negative groups (for all, p>0.05). Although HDV-RNA was notdetectable in all studied samples, only one subject had detectable HBV-DNA in the anti-HDV-positive group.CONCLUSION: This study highlighted the prevalence of anti-HDV among subjects who had resolved HBV infection. Longtermfollow-up studies, including after the resolution of both infections, are needed to explore HBV–HDV interactions and thebehavioral patterns of these viruses.

🔖

Bu Makaleye Atıf Yap

POYRAZOĞLU, O. K., AKBULUT, H., YALNIZ, M., ŞAHİN, A., TORAMAN, Z. A., GÜROCAK, S., BAHÇECİOĞLU, İ. H., TUNÇ, N., DEMİREL, U. (2022). Anti-HDV seroprevalance among patients with previous HBV infection. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 2, 132–138. https://ajindex.com/articles/551519

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. An update on HDV: virology, pathogenesis and treatment. Antivir Ther 2013;18:541–8.
  2. Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016;64:S102–16. Rizzetto M. Current management of delta hepatitis. Liver Int 2013;33 Suppl 1:195–7.
  3. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep 2014;16:365. Türkdoğan MK, Bozkurt H, Uygan I, Tuncer I, Irmak H, Buzgan T, et al. Chronic hepatitis delta virus infection in Van region of eastern Turkey. Turk J Gastroenterol 2005;16:17–20.
  4. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat 2011;18:518–24.
  5. Değertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008;28:494–8.
  6. Kose S, Ece G, Gozaydin A, Turken M. Study on seroprevalence of hepatitis delta in a regional hospital in western Turkey. J Infect Dev Ctries 2012;6:782–5.
  7. Reinheimer C, Doerr HW, Berger A. Hepatitis delta: on soft paws across Germany. Infection 2012;40:621–5.
  8. Stroffolini T, Sagnelli E, Sagnelli C, Russello M, De Luca M, Rosina F, et al; behalf of EPACRON study group. Hepatitis delta infection in Italian patients: towards the end of the story? Infection 2017;45:277–81.
  9. Celen MK, Ayaz C, Hosoglu S, Geyik MF, Ulug M. Anti-hepatitis delta virus seroprevalence and risk factors in patients with hepatitis B in Southeast Turkey. Saudi Med J 2006;27:617–20.
  10. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627–31.
  11. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–52.
  12. Yuan T, Jiang Y, Li M, Li W. Chronic hepatitis B surface antigen seroclearance- related immune factors. Hepatol Res 2017;47:49–59.
  13. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531–7.
  14. Terrault NA, Bzowej NH, Chang